Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clopidogrel - Sanofi

Drug Profile

Clopidogrel - Sanofi

Alternative Names: DV-7314; Iscover; PCR 4099; Plavix; SR 25989C; SR 25990C

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Bristol-Myers Squibb; Sanofi
  • Class 2 ring heterocyclic compounds; Anti-ischaemics; Antiplatelets; Antithrombotics; Cardiovascular therapies; Chlorobenzenes; Esters; Ischaemic heart disorder therapies; Pyridines; Small molecules; Thienopyridines; Vascular disorder therapies
  • Mechanism of Action Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Angina pectoris; Atherosclerosis; Cardiovascular disorders; Ischaemic heart disorders; Myocardial infarction; Peripheral arterial occlusive disorders; Stroke; Unstable angina pectoris
  • Discontinued Congenital heart defects; Coronary thrombosis

Most Recent Events

  • 06 Jan 2020 Discontinued - Phase-III for Coronary thrombosis in Canada (PO) (Sanofi website, January 2020)
  • 15 Mar 2016 Biomarkers information updated
  • 04 Oct 2012 Bristol-Myers Squibb intends to terminate its licence for clopidogrel in all countries except USA and Puerto Rico, effective 1 January 2013
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top